The incidence of metastases to the pancreas is very low, and the benefit of resection for these is unclear.
In this study, researchers from Italy evaluated the outcome of patients undergoing pancreatic resection for metastatic tumors to the pancreas.
The team assessed 8 patients who underwent pancreatic resection for metastatic tumors, between 1980 and 2001.
They established that the primary cancer was colon carcinoma in 4 cases, renal cell cancer in 2, duodenal leiomyosarcoma in 1, and malignant fibrous histiocytoma in 1.
The median interval between primary treatment and detection of pancreatic metastases was 36 months.
The researchers found that in 2 cases pancreatic metastases were synchronous with the primary tumor.
|50% of patients remained alive 14 to 31 months after surgery.|
|Journal of Surgical Oncology|
Of the 8 patients in the study, 4 underwent pancreatoduodenectomy, 2 distal pancreatectomy, 1 total pancreatectomy, and 1 median pancreatectomy.
The team determined that associated resection of extrapancreatic lesions was performed in 4 patients.
They found no postoperative mortality. However, 2 patients had a pancreatic and a biliary fistula.
Survival averaged 23 months. The team found that 4 patients died of metastatic disease 14 to 42 months after the operation.
However, 4 patients remained alive 14 to 31 months after surgery.
Dr Cosimo Sperti's team concluded, "Pancreatic resection for metastatic disease to the pancreas should be considered even in selected patients with limited extrapancreatic disease".
"Long-term survival or good palliation may be achieved".